TransMedics Group (TMDX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.51
- Estimate
- $0.29
- Surprise
- +73.8%
- Revenue (period 2026-09-30)
- $203.0M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
TransMedics Group (TMDX) beat the $0.29 estimate with adjusted EPS of $0.51 — a large 73.8% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates TMDX Sell at 5.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +73.8% surprise compares with a +14.1% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive news sentiment (+1.00)
What argues against it
- Concentration risk — Supplier: third-party sterilization vendors
- Analyst target reached - limited upside remaining
- Leverage penalty (D/E 1.7): -1.0
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $85.44
- Price target
- $85.89
- Stop
- $79.46
- Upside to target
- +0.5%
- Reward-to-risk
- 0.0:1
Forward estimates sit below the trailing run-rate (30.6× forward vs 17.9× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
TMDX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $2.38B
- P/E (fwd)
- 30.6
- P/E (ttm)
- 17.9
- 52-week range
- $60.10–$156.00
- Off 52-week high
- 45.2%
- RSI (14)
- 68
- Volume vs avg
- 1.30×
- Score today
- 5.5/10